MCID: PRM051
MIFTS: 50

Primary Pigmented Nodular Adrenocortical Disease malady

Categories: Genetic diseases, Rare diseases, Reproductive diseases, Endocrine diseases

Aliases & Classifications for Primary Pigmented Nodular Adrenocortical Disease

About this section

Aliases & Descriptions for Primary Pigmented Nodular Adrenocortical Disease:

Name: Primary Pigmented Nodular Adrenocortical Disease 10 45 12 51
Ppnad 45 51
 
Pigmented Nodular Adrenocortical Disease, Primary, 2 36
Pigmented Nodular Adrenocortical Disease, Primary, 1 36

Characteristics:

Orphanet epidemiological data:

51
primary pigmented nodular adrenocortical disease:
Inheritance: Autosomal dominant; Age of onset: All ages; Age of death: any age

Classifications:



External Ids:

Disease Ontology10 DOID:0060280
Orphanet51 189439
ICD10 via Orphanet28 E24.8
UMLS65 C1864846, C1864851

Summaries for Primary Pigmented Nodular Adrenocortical Disease

About this section
Disease Ontology:10 An adrenal cortex disease characterized by small to normal sized adrenal glands containing multiple small cortical pigmented nodules.

MalaCards based summary: Primary Pigmented Nodular Adrenocortical Disease, also known as ppnad, is related to pigmented nodular adrenocortical disease, primary, 3 and pigmented nodular adrenocortical disease, primary, 4, and has symptoms including hypercortisolism, abnormality of the genital system and diabetes mellitus. An important gene associated with Primary Pigmented Nodular Adrenocortical Disease is PRKAR1A (Protein Kinase CAMP-Dependent Type I Regulatory Subunit Alpha), and among its related pathways are Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics and G alpha (s) signalling events. Affiliated tissues include cortex, adrenal gland and adrenal cortex, and related mouse phenotypes are renal/urinary system and tumorigenesis.

Related Diseases for Primary Pigmented Nodular Adrenocortical Disease

About this section

Diseases in the Primary Pigmented Nodular Adrenocortical Disease family:

Pigmented Nodular Adrenocortical Disease, Primary, 2 Pigmented Nodular Adrenocortical Disease, Primary, 3
Pigmented Nodular Adrenocortical Disease, Primary, 1 Pigmented Nodular Adrenocortical Disease, Primary, 4

Diseases related to Primary Pigmented Nodular Adrenocortical Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 186)
idRelated DiseaseScoreTop Affiliating Genes
1pigmented nodular adrenocortical disease, primary, 312.2
2pigmented nodular adrenocortical disease, primary, 412.2
3pigmented nodular adrenocortical disease, primary, 212.0
4pigmented nodular adrenocortical disease, primary, 112.0
5acth-independent macronodular adrenal hyperplasia10.6
6lung squamous cell carcinoma10.5POMC, SYP
7ureter transitional cell carcinoma10.5CHGA, SYP
8gallbladder small cell carcinoma10.5CHGA, SYP
9pediculus humanus capitis infestation10.5CHGA, SYP
10childhood malignant hemangiopericytoma10.5CHGA, SYP
11classic pulmonary blastoma10.4CTNNB1, SYP
12oxyphilic adenoma10.4CHGA, SYP
13perineural angioma10.4CHGA, SYP
14middle cerebral artery infarction10.4CHGA, SYP
15thoracic benign neoplasm10.4CHGA, SYP
16urinary system disease10.4CHGA, SYP
17peritoneal serous adenocarcinoma10.4CHGA, SYP
18goldmann-favre syndrome10.4CHGA, CTNNB1
19urethra adenocarcinoma10.4CHGA, SYP
20scabies10.4CHGA, SYP
21nodular tenosynovitis10.4ESR1, SYP
22graphite pneumoconiosis10.4CHGA, SYP
23wheat allergy10.4CHGA, SYP
24ovarian cystic teratoma10.4CHGA, POMC
25pinheiro freire-maia miranda syndrome10.4CHGA, SYP
26villous adenocarcinoma10.4CHGA, POMC
27thoracic aortic aneurysm10.4
28aortic aneurysm10.4
29aneurysm10.4
30corneal ectasia10.4CHGA, POMC
31pancreatic solid pseudopapillary carcinoma10.4CHGA, SYP
32cerebellar astrocytoma10.4CHGA, SYP
33adrenal gland pheochromocytoma10.4POMC, PRKAR1A, SYP
34cardiovascular organ benign neoplasm10.3CTNNB1, POMC, SYP
35syringoma10.3ESR1, PGR
36endocrine organ benign neoplasm10.3ESR1, PGR
37cervical benign neoplasm10.3ESR1, PGR
38ovary neuroendocrine neoplasm10.3CTNNB1, PGR
39large bowel leiomyoma10.3ESR1, PGR
40bile duct cystadenoma10.3ESR1, PGR
41glaucoma iridogoniodysgenesia10.3ESR1, PGR
42venous tributary occlusion of retina10.3ESR1, PGR
43mixed type thymoma10.3CHGA, POMC, SYP
44gastrointestinal system disease10.3CHGA, SYP
45gangliocytoma10.3NCAM1, SYP
46peroneal nerve paralysis10.3ESR1, PGR
47situs inversus10.3ESR1, PGR
48colon mucinous adenocarcinoma10.3CHGA, CTNNB1, SYP
49pancreatic signet ring cell adenocarcinoma10.3NCAM1, SYP
50vulvar squamous papilloma10.3ESR1, PGR

Graphical network of the top 20 diseases related to Primary Pigmented Nodular Adrenocortical Disease:



Diseases related to primary pigmented nodular adrenocortical disease

Symptoms for Primary Pigmented Nodular Adrenocortical Disease

About this section

Symptoms:

 51 (show all 15)
  • adrenal glands anomalies
  • cortico-adrenal hyperplasia/hypersecretion
  • striae
  • thin skin
  • chronic arterial hypertension
  • diabetes mellitus
  • late puberty/hypogonadism/hypogenitalism
  • muscle weakness/flaccidity
  • muscle hypotrophy/atrophy/dystrophy/agenesis/amyotrophy
  • osteoporosis/osteopenia/demineralisation/osteomalacia/rickets
  • mutiple fractures/bone fragility
  • truncal obesity
  • short stature/dwarfism/nanism
  • asthenia/fatigue/weakness
  • myopathy

HPO human phenotypes related to Primary Pigmented Nodular Adrenocortical Disease:

(show all 13)
id Description Frequency HPO Source Accession
1 hypercortisolism hallmark (90%) HP:0001578
2 abnormality of the genital system typical (50%) HP:0000078
3 diabetes mellitus typical (50%) HP:0000819
4 hypertension typical (50%) HP:0000822
5 thin skin typical (50%) HP:0000963
6 striae distensae typical (50%) HP:0001065
7 muscle weakness typical (50%) HP:0001324
8 truncal obesity typical (50%) HP:0001956
9 recurrent fractures typical (50%) HP:0002757
10 skeletal muscle atrophy typical (50%) HP:0003202
11 short stature typical (50%) HP:0004322
12 reduced bone mineral density typical (50%) HP:0004349
13 myopathy occasional (7.5%) HP:0003198

Drugs & Therapeutics for Primary Pigmented Nodular Adrenocortical Disease

About this section

Drugs for Primary Pigmented Nodular Adrenocortical Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
EpinephrineapprovedPhase 283451-43-45816
Synonyms:
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-dihydroxy-a-[(methylamino)methyl]-Benzyl alcohol
(-)-3,4-dihydroxy-alpha-[(methylamino)methyl]-Benzyl alcohol
(-)-Adrenalin
(-)-Adrenaline
(-)-Epinephrine
(-)-R-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-(−)-adrenaline
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-4-[1-hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
(R)-Adrenaline
(R)-Epinephrine
(−)-adrenaline
02252_FLUKA
1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
1-Adrenalin
1-Epinephrine
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
51-43-4
51-43-4 (FREE BASE)
51028-73-0
A0173
AC-13188
AC1L1L7B
ADR ADRENALINE
ADROP
AI3-19015
Adnephrine
Adrenaclick
Adrenal
Adrenalin
Adrenalin (TN)
Adrenalin in Oil
Adrenalin-Medihaler
Adrenalina
Adrenalina [DCIT]
Adrenaline
Adrenaline (JP15)
Adrenaline/Epinephrine
Adrenalinum
Adrenamine
Adrenan
Adrenapax
Adrenasol
Adrenatrate
Adrenine
Adrenodis
Adrenohorma
Adrenosan
Adrenutol
Adrin
Adrine
Ana-Guard
Ana-Kit
Antiasthmatique
Asmatane Mist
Asthma meter mist
Asthma-nefrin
Asthmahaler Mist
Asthmanefrin
Astmahalin
Astminhal
Auvi-q
BIDD:GT0119
Balmadren
Bernarenin
Biorenine
Bosmin
Brevirenin
Bronkaid
Bronkaid Mist
Bronkaid Suspension Mist
Bupivacaine Hcl and Epinephrine
C00788
CCRIS 4812
CHEBI:28918
CHEMBL679
CID5816
Chelafrin
Citanest Forte
Corisol
D-Epifrin
D-Epinephrine
D00095
DB00668
Drenamist
Dylephrin
Dyspne-Inhal
E4250_SIGMA
EINECS 200-098-7
EPI E Z PEN JR
EPIPEN E Z PEN
EPIPEN JR
Epi EZ Pen Jr
Epifrin
Epiglaufrin
Epinefrin
Epinefrin [Czech]
Epinefrina
Epinefrina [INN-Spanish]
Epinephran
Epinephrin
Epinephrine
Epinephrine (USP)
Epinephrine (USP/INN)
Epinephrine [USAN:INN:JAN]
Epinephrine bitartrate
Epinephrine chloride
Epinephrine hydrochloride
Epinephrinum
Epinephrinum [INN-Latin]
Epipen
Epipen (TN)
Epipen Auto-Injector
Epipen EZ Pen
Epipen Jr
Epipen Jr.
Epipen Jr. Auto-Injector
Epipen jr
Epirenamine
Epirenan
Epirenin
Epitrate
Eppy
 
Esphygmogenina
Exadrin
Glaucon
Glaucosan
Glauposine
Glycirenan
HSCI1_000215
HSDB 4289
Haemostasin
Haemostatin
Hektalin
Hemisine
Hemostasin
Hemostatin
Hypernephrin
Hyporenin
IOP
Intranefrin
Iontocaine
Isoptoepinal
Kidoline
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-Adrenaline Base
L-Epinehphrine
L-Epinephrine
L-Epirenamine
L-Methylaminoethanolcatechol
L-epinephrine
LS-156
Levo-Methylaminoethanolcatechol
Levoadrenaline
Levoepinephrine
Levorenen
Levorenin
Levorenine
Levoreninum
Lopac-E-4642
Lyodrin
Lyophrin
Medihaler-Epi
Metanephrin
Methylaminoethanolcatechol
Methylarterenol
Micronefrin
Micronephrine
MolPort-002-051-368
Mucidrina
Myosthenine
Mytrate
NCGC00015417-01
NCGC00142615-01
NCGC00142615-03
NCGC00142615-04
NCGC00142615-05
NCGC00142615-06
NCGC00142615-07
NSC 62786
NSC62786
Nephridine
Nieraline
PDSP1_001120
PDSP2_001104
Paranephrin
Primatene
Primatene Mist
Primatene Mist Refill
Prime Asthma Relief
R-(-)-Epinephrine
R-Adrenaline
RCRA waste no. P042
Racemic Epinephrine
Racepinephrine
Rcra waste number P042
Renagladin
Renaglandin
Renaglandulin
Renaleptine
Renalina
Renoform
Renostypricin
Renostypticin
Renostyptin
SMP1_000227
ST069368
SUS-PHRINE SULFITE-FREE
Scurenaline
Septocaine
Simplene
Sindrenina
Soladren
Sphygmogenin
Stryptirenal
Styptirenal
Supracapsulin
Supradin
Supranefran
Supranephrane
Supranephrine
Supranol
Suprarenaline
Suprarenin
Suprel
Surenine
Surrenine
Sus-Phrine
Sus-phrine
Susphrine
Sympathin I
Takamina
Takamine
Tokamina
Tonogen
Twinject
Twinject 0.15
Twinject 0.3
Twinject 0.30
UNII-YKH834O4BH
Vaponefrin
Vasoconstrictine
Vasoconstrictor
Vasodrine
Vasoton
Vasotonin
adrenaline
bmse000316
d-Adrenaline
epinephrine
l-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
l-Adrenalin
l-Adrenaline
l-Epinephine
l-Epinephrine (synthetic)
l-Epirenamine
l-Methylaminoethanolcatechol
levoepinephrine
nchembio747-comp9
2RacepinephrinePhase 2834
3Epinephryl boratePhase 2834
4Adrenocorticotropic HormonePhase 2133

Interventional clinical trials:

idNameStatusNCT IDPhase
1Study of Efficacy and Safety of Osilodrostat in Cushing's SyndromeRecruitingNCT02468193Phase 2
2Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney ComplexRecruitingNCT00001452
3Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the CARNEY Complex (CNC)Active, not recruitingNCT00668291

Search NIH Clinical Center for Primary Pigmented Nodular Adrenocortical Disease


Cochrane evidence based reviews: pigmented nodular adrenocortical disease, primary, 2

Genetic Tests for Primary Pigmented Nodular Adrenocortical Disease

About this section

Anatomical Context for Primary Pigmented Nodular Adrenocortical Disease

About this section

MalaCards organs/tissues related to Primary Pigmented Nodular Adrenocortical Disease:

33
Cortex, Adrenal gland, Adrenal cortex, Bone, Skin, Skeletal muscle, Breast

Animal Models for Primary Pigmented Nodular Adrenocortical Disease or affiliated genes

About this section

MGI Mouse Phenotypes related to Primary Pigmented Nodular Adrenocortical Disease:

38 (show all 11)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053678.4CHGA, CTNNB1, ESR1, ESR2, PDE8B, POMC
2MP:00020068.2CTNNB1, ESR1, ESR2, PGR, POMC, PRKACA
3MP:00053797.9CHGA, CTNNB1, ESR1, ESR2, PGR, POMC
4MP:00053857.7CHGA, CTNNB1, ESR1, ESR2, PGR, POMC
5MP:00036316.7CTNNB1, ESR1, ESR2, NCAM1, PDE11A, POMC
6MP:00053866.4CTNNB1, ESR1, ESR2, NCAM1, PDE11A, PGR

Publications for Primary Pigmented Nodular Adrenocortical Disease

About this section

Articles related to Primary Pigmented Nodular Adrenocortical Disease:

(show top 50)    (show all 57)
idTitleAuthorsYear
1
Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC. (26461266)
2015
2
Clinical Features Predictive of High-Risk Retinoblastoma in 403 Asian Indian Patients: A Case-Control Study. (25841975)
2015
3
Crown lengthening procedure in the management of amelogenesis imperfecta. (26538965)
2015
4
Tension Pneumothorax and Subcutaneous Emphysema Complicating Insertion of Nasogastric Tube. (26448883)
2015
5
A Multipurpose High Throughput SNP Chip for the Dengue and Yellow Fever Mosquito, Aedes aegypti. (25721127)
2015
6
Sacral neuromodulation for faecal incontinence: is the outcome compromised in patients with high-grade internal rectal prolapse? (25433818)
2015
7
Lipoprotein(a) concentrations in adult congenital heart disease patients. (23701863)
2014
8
Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. (25003325)
2014
9
Syncope associated with water pipe smoking. (23606397)
2013
10
Pathogenic mutation of ALK2 inhibits induced pluripotent stem cell reprogramming and maintenance: mechanisms of reprogramming and strategy for drug identification. (22949078)
2012
11
A role for PP1/NIPP1 in steering migration of human cancer cells. (22815811)
2012
12
Molecular biomarkers and ablative therapies for Barrett's esophagus. (23061708)
2012
13
Dynamic and transient interactions of Atg9 with autophagosomes, but not membrane integration, are required for autophagy. (22456507)
2012
14
The ribosome-related protein, SBDS, is critical for normal erythropoiesis. (21963601)
2011
15
Urokinase plasminogen activator receptor is expressed in invasive cells in gastric carcinomas from high- and low-risk countries. (19609941)
2010
16
Altered sensitivity to rewarding and aversive drugs in mice with inducible disruption of cAMP response element-binding protein function within the nucleus accumbens. (19211892)
2009
17
Characterization of hormone receptor status in 5758 Chinese females with breast cancer]. (20021865)
2009
18
Characteristic imprint of single nucleotide polymorphisms in multiple sclerosis. (18720029)
2009
19
Rhucin, a recombinant C1 inhibitor for the treatment of hereditary angioedema and cerebral ischemia. (18311668)
2008
20
Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal clear-cell carcinoma of intermediate prognosis. Results and conclusions from a combined analysis. (18587246)
2008
21
Interpolation of the subjective score of visually-induced motion sickness by using physiological parameters. (19163739)
2008
22
Laboratory evaluation of a simple and rapid latex agglutination assay for the serodiagnosis of typhoid fever. (17673269)
2007
23
UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. (16710296)
2006
24
PTEN is recruited to specific microdomains of the plasma membrane during lactacystin-induced neuronal apoptosis. (16857313)
2006
25
Hepatoma-derived growth factor. Significance of amino acid residues 81-100 in cell surface interaction and proliferative activity. (15655245)
2005
26
Targeting of the virulence factor acetohydroxyacid synthase by sulfonylureas results in inhibition of intramacrophagic multiplication of Brucella suis. (16127072)
2005
27
The RacGEF Tiam1 inhibits migration and invasion of metastatic melanoma via a novel adhesive mechanism. (15340013)
2004
28
Lack of contribution of 11betaHSD1 and glucocorticoid action to reduced muscle mass associated with reduced growth hormone action. (15519255)
2004
29
Hantavirus pulmonary syndrome--United States: updated recommendations for risk reduction. Centers for Disease Control and Prevention. (12194506)
2002
30
Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. (11936520)
2002
31
What are the causes of protein-energy malnutrition in chronic renal insufficiency? (11840387)
2002
32
No association of the HLA-A2 allele with Alzheimer's disease. (12459502)
2002
33
Rosai-Dorfman disease presenting with isolated bilateral orbital masses: report of two cases. (11498433)
2001
34
Altered expression of heme oxygenase-1 in the livers of patients with portal hypertensive diseases. (11124818)
2001
35
Inhibitory effects of green tea and grape juice on the phenol sulfotransferase activity of mouse intestines and human colon carcinoma cell line, Caco-2. (10864017)
2000
36
Methemoglobinemia induced by combined use of sodium nitrate and acetoaminophen. (11030216)
2000
37
Wernicke encephalopathy-like symptoms as an early manifestation of Creutzfeldt-Jakob disease in a chronic alcoholic. (10371084)
1999
38
A novel calcium-independent phospholipase A2, cPLA2-gamma, that is prenylated and contains homology to cPLA2. (9705332)
1998
39
Colloid cyst of the third ventricle in opposite sex, non-twin siblings. (18639013)
1998
40
Pharmacology of irinotecan. (14988754)
1998
41
Enhanced glial cell line-derived neurotrophic factor mRNA expression upon (-)-deprenyl and melatonin treatments. (9726430)
1998
42
Hippocampal cholinergic blockade enhances hypothalamic-pituitary-adrenal responses to stress. (9359609)
1997
43
Patterns of intermediate filaments, VLA integrins and HLA antigens in a new human biliary epithelial cell line sensitive to interferon-gamma. (9210616)
1997
44
Receptor-associated protein is a folding chaperone for low density lipoprotein receptor-related protein. (8703036)
1996
45
Growth factors in invertebrate in vitro culture. (1869490)
1991
46
GABA synthesis in brain slices is dependent on glutamine produced in astrocytes. (1881516)
1991
47
Endodermal sinus tumor in pregnancy: report of a case and review of the literature. (6190713)
1983
48
Diffuse benign peritoneal mesothelioma. (7288698)
1981
49
Leukopenia secondary to sulfadiazine silver. (430776)
1979
50
A reciprocal translocation (X;11) in a female with gonadal dysgenesis. (519895)
1979

Variations for Primary Pigmented Nodular Adrenocortical Disease

About this section

Expression for genes affiliated with Primary Pigmented Nodular Adrenocortical Disease

About this section
Search GEO for disease gene expression data for Primary Pigmented Nodular Adrenocortical Disease.

Pathways for genes affiliated with Primary Pigmented Nodular Adrenocortical Disease

About this section

Pathways related to Primary Pigmented Nodular Adrenocortical Disease according to GeneCards Suite gene sharing:

(show top 50)    (show all 80)
idSuper pathwaysScoreTop Affiliating Genes
19.5ESR1, ESR2
29.4CHGA, PDE11A, PDE8B, POMC
39.2PRKACA, PRKACB, PRKACG
49.2PRKACA, PRKACB, PRKACG
59.2PRKACA, PRKACB, PRKACG
69.2PRKACA, PRKACB, PRKACG
78.9CHGA, PRKACA, PRKACB, PRKACG
88.9CHGA, PRKACA, PRKACB, PRKACG
98.8ESR1, PRKACA, PRKACB, PRKACG
10
Show member pathways
8.6PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
11
Show member pathways
8.6PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
12
Show member pathways
8.6PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
13
Show member pathways
8.6PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
14
Show member pathways
8.6PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
15
Show member pathways
8.6PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
16
Show member pathways
8.6PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
17
Show member pathways
8.6PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
188.6PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
19
Show member pathways
8.6PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
20
Show member pathways
8.6PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
218.6PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
228.6PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
238.6PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
248.6PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
258.6PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
268.6PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
278.6PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
288.6PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
298.6PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
308.6PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
31
Show member pathways
8.6CTNNB1, POMC, PRKACA, PRKACB, PRKACG
328.6CHGA, POMC, PRKACA, PRKACB, PRKACG
338.5CTNNB1, ESR1, PRKACA, PRKACB, PRKACG
348.5CTNNB1, ESR1, PRKACA, PRKACB, PRKACG
358.4NCAM1, PRKACA, PRKACB, PRKACG
36
Show member pathways
8.4PDE8B, PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
378.3POMC, PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
38
Show member pathways
8.3POMC, PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
39
Show member pathways
8.3CTNNB1, PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
40
Show member pathways
8.3CTNNB1, PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
41
Show member pathways
8.3CTNNB1, PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
42
Show member pathways
8.3CTNNB1, PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
438.3CTNNB1, PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
44
Show member pathways
8.3CTNNB1, PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
458.2CTNNB1, ESR2, PRKACA, PRKACB, PRKAR1A, PRKAR1B
46
Show member pathways
8.0CHGA, POMC, PRKACA, PRKACB, PRKACG, PRKAR1A
47
Show member pathways
7.7ESR1, ESR2, PRKACA, PRKACB, PRKACG, PRKAR1A
48
Show member pathways
7.6CHGA, CTNNB1, ESR1, ESR2, PRKACA, PRKACB
49
Show member pathways
7.4CTNNB1, ESR1, ESR2, PRKACA, PRKACB, PRKACG
50
Show member pathways
5.3CHGA, CTNNB1, ESR1, NCAM1, PDE11A, PDE8B

GO Terms for genes affiliated with Primary Pigmented Nodular Adrenocortical Disease

About this section

Cellular components related to Primary Pigmented Nodular Adrenocortical Disease according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1ciliary baseGO:009754610.1PRKACA, PRKAR1A, PRKAR1B
2cytosolGO:00058298.4CTNNB1, ESR1, PRKACA, PRKACB, PRKAR1A, PRKAR1B

Biological processes related to Primary Pigmented Nodular Adrenocortical Disease according to GeneCards Suite gene sharing:

(show all 18)
idNameGO IDScoreTop Affiliating Genes
1negative regulation of cAMP-dependent protein kinase activityGO:200048010.6PRKAR1A, PRKAR1B
2activation of protein kinase A activityGO:003419910.4PRKACA, PRKACB
3Sertoli cell developmentGO:006000910.3ESR1, ESR2
4Sertoli cell proliferationGO:006001110.2ESR1, ESR2
5regulation of neuron apoptotic processGO:004352310.2ESR1, ESR2
6response to hormoneGO:000972510.1CTNNB1, ESR2
7triglyceride catabolic processGO:00194339.9PRKACA, PRKACB, PRKACG
8activation of phospholipase C activityGO:00072029.7PRKACA, PRKACB, PRKACG
9renal water homeostasisGO:00030919.6PRKACA, PRKACG, PRKAR1A, PRKAR1B
10negative regulation of neuron deathGO:19012159.4CHGA, CTNNB1, ESR1, ESR2
11water transportGO:00068339.4PRKACB, PRKACG, PRKAR1A, PRKAR1B
12cellular response to glucagon stimulusGO:00713779.2PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
13epidermal growth factor receptor signaling pathwayGO:00071739.1NCAM1, PRKACG, PRKAR1A, PRKAR1B
14energy reserve metabolic processGO:00061129.0PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
15fibroblast growth factor receptor signaling pathwayGO:00085438.2NCAM1, PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
16innate immune responseGO:00450877.8NCAM1, PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
17neurotrophin TRK receptor signaling pathwayGO:00480117.7NCAM1, PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B
18signal transductionGO:00071657.7CTNNB1, PGR, POMC, PRKACA, PRKACB, PRKACG

Molecular functions related to Primary Pigmented Nodular Adrenocortical Disease according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
13,5-cyclic-AMP phosphodiesterase activityGO:000411510.0PDE11A, PDE8B
2cAMP-dependent protein kinase activityGO:00046919.7PRKACB, PRKACG
3core promoter sequence-specific DNA bindingGO:00010469.5ESR1, ESR2

Sources for Primary Pigmented Nodular Adrenocortical Disease

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet